Analysis Group

Report: 74% of medicines in development could be first-in-class treatments

Thursday, July 20, 2017

Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

[Read More]

Dr. Anita J. Chawla joins CytRx board of directors

Thursday, March 12, 2015

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Anita J. Chawla, Ph.D., to its board of directors. Chawla brings over 25 years of experience as an economist in the health care industry to CytRx, with a proven track record helping pharmaceutical, biotechnology, medical device and diagnostic companies achieve their product development and commercialization objectives.

[Read More]